BlueCross BlueShield
Federal Employee Program
Federal Employee Program®
1310 G Street, N.W.
Washington, D.C. 20005
202.942.1000
Fax 202.942.1125

5.21.52

Section:	Prescription Drugs	**Effective Date:**	July 1, 2022
Subsection:	Antineoplastic Agents	**Original Policy Date:**	January 16, 2015
Subject:	Lynparza	**Page:**	1 of 7

Last Review Date: June 16, 2022

Lynparza

Description

Lynparza (olaparib)

Background
Lynparza (olaparib) is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Lynparza inhibits growth of select tumor cell lines and decreases tumor growth (1).

Regulatory Status
FDA-approved indications: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: (1)

1. Ovarian cancer
    a. For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic *BRCA*-mutated (g*BRCA*m or s*BRCA*m) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
    b. In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:
        i. a deleterious or suspected deleterious *BRCA* mutation, and/or
        ii. genomic instability

   c. For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy
   d. For the treatment of adult patients with deleterious or suspected deleterious germline *BRCA* mutated advanced ovarian cancer who has been treated with three or more prior lines of chemotherapy
2. Breast cancer
   a. For the adjuvant treatment of adult patients with deleterious or suspected deleterious g*BRCA*m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy
   b. For the treatment of breast cancer in in patients with deleterious or suspected deleterious g*BRCA*m, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment
3. Pancreatic cancer
   a. For the maintenance treatment of adult patients with deleterious or suspected deleterious g*BRCA*m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
4. Prostate cancer
   a. For the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Lynparza is associated with the development of myelodysplastic syndrome, acute myeloid leukemia, and pneumonitis (1).

The safety and effectiveness of Lynparza in patients less than 18 years of age have not been established (1).

Related policies
Rubraca, Talzenna, Zejula

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Lynparza may be considered **medically necessary** for use in patients 18 years of age or older with advanced ovarian cancer, recurrent or advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, early breast cancer, metastatic breast cancer, metastatic pancreatic cancer, or metastatic castration-resistant prostate cancer and if the conditions indicated below are met.

Lynparza may be considered **investigational** in patients less than 18 years of age and for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Advanced ovarian cancer
    a. *BRCA*-positive mutation
    b. Prior therapy with 3 or more lines of chemotherapy

2. Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    a. Patient has had a complete or partial response to platinum-based chemotherapy

3. Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
    a. Patient has had a complete or partial response to platinum-based chemotherapy and **ONE** of the following:
        1. *BRCA*-positive mutation
        2. Used in combination with bevacizumab
            a. Cancer is associated with homologous recombination deficiency (HRD) positive status defined by at least **ONE** of the following:
                i. Deleterious or suspected deleterious *BRCA* mutation
                ii. Genomic instability

4. Early breast cancer
    a. High risk
    b. *BRCA*-positive mutation
    c. HER2-negative
    d. Previously treated with neoadjuvant or adjuvant chemotherapy

5. Metastatic breast cancer
    a. *BRCA*-positive mutation
    b. HER2-negative
    c. Prior therapy with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting
    d. If HR-positive must have **ONE** of the following:
        i. Previously been treated with prior endocrine therapy
        ii. Considered an inappropriate candidate for endocrine therapy

6. Metastatic pancreatic cancer
    a. *BRCA*-positive mutation
    b. Disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

7. Metastatic castration-resistant prostate cancer (mCRPC)
    a. Homologous recombination repair (HRR) gene mutation
    b. Disease progressed following prior treatment with enzalutamide or abiraterone
    c. Patient has had a bilateral orchiectomy **OR** patient will be receiving a gonadotropin-releasing hormone (GnRH) analog concurrently

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Advanced ovarian cancer
2. Recurrent or advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

3. Metastatic breast cancer
4. Metastatic pancreatic cancer
5. Metastatic castration-resistant prostate cancer (mCRPC)

AND the following for all indications:

a. **NO** disease progression or unacceptable toxicity

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity

Strength	Quantity
100 mg	360 tablets per 90 days
150 mg	

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above*

***NO** renewal for early breast cancer

Rationale

Summary

Lynparza (olaparib) is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Lynparza inhibits growth of select tumor cell lines and decreases tumor growth. The safety and effectiveness of Lynparza in patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Lynparza while maintaining optimal therapeutic outcomes.

References

1. Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022.
2. NCCN Drugs & Biologics Compendium® Olaparib 2022. National Comprehensive Cancer Network, Inc. Accessed on May 9, 2022.

Policy History

Date	Action
January 2015	Addition to PA
March 2015	Annual review and reference update
June 2016	Annual editorial review and reference update Policy change from 5.04.52 to 5.21.52
June 2017	Annual editorial review and reference update Addition of unacceptable toxicity to renewal section
September 2017	Annual review Addition of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer Addition of quantity limits Removal of no concurrent therapy with other agents for the treatment of ovarian cancer
February 2018	Addition of metastatic breast cancer to initiation and renewal criteria. Addition of *BRCA* positive, prior therapy with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and If HR-positive, must have previously been treated with prior endocrine therapy, or be considered an inappropriate candidate for endocrine therapy to initiation criteria for the diagnosis of metastatic breast cancer Change in quantity for the 50mg capsules from 672 to 1456
March 2018	Annual review
January 2019	Addition of new indication: *BRCA*-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Removal of Lynparza 50mg capsules
March 2019	Annual review
May 2019	Changed quantity limit to 360 tablets per 90 days for both strengths of Lynparza
June 2019	Annual review
January 2020	Addition of indication: metastatic pancreatic cancer
March 2020	Annual review
May 2020	Addition of indication: used in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is

	associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious *BRCA* mutation, and/or genomic instability. Addition of indication: treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone
September 2020	Annual review
June 2021	Annual review and reference update
February 2022	Changed initiation duration from 6 to 12 months per FEP
April 2022	Addition of indication per PI update: early breast cancer
June 2022	Annual review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.